Last update 01 Nov 2024

Pierre Fabre Médicament Production SAS

Subsidiary Company|
1991|
France

Overview

Tags

Skin and Musculoskeletal Diseases
Neoplasms
Cardiovascular Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Endocrinology and Metabolic Disease2
Nervous System Diseases2
Immune System Diseases2
Hemic and Lymphatic Diseases2
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
BRAF(Serine/threonine-protein kinase B-raf)1
MEK1 x MEK21
Tubulin1

Related

4
Drugs associated with Pierre Fabre Médicament Production SAS
Binimetinib
Target
MEK1 x MEK2
Mechanism
MEK1 inhibitors [+1]
Active Org.
Pierre Fabre Médicament SAS [+10]
Originator Org.
Array BioPharma, Inc.Array BioPharma, Inc.
Active Indication
BRAF mutated anaplastic thyroid cancer [+32]
Inactive Indication
Acute Myeloid Leukemia [+33]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date27 Jun 2018
Encorafenib
Target
BRAF
Mechanism
BRAF inhibitors
Active Org.
Pfizer Inc.Pfizer Inc. [+9]
Originator Org.
Array BioPharma, Inc.Array BioPharma, Inc.
Active Indication
BRAF mutated anaplastic thyroid cancer [+24]
Inactive Indication
Glioblastoma Harboring BRAF V600 Mutation [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date27 Jun 2018
Vinflunine
Target
Tubulin
Mechanism
Tubulin inhibitors
Active Org.
Pierre Fabre SAPierre Fabre SA [+2]
Originator Org.
Pierre Fabre SAPierre Fabre SA
Active Indication
Bladder Cancer [+2]
Inactive Indication
Advanced cancer [+19]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
EU [+3]
First Approval Date21 Sep 2009
7
Clinical Trials associated with Pierre Fabre Médicament Production SAS
CTR20211613 / CompletedPhase 1
在BRAF V600E突变的中国晚期转移性实体瘤患者中研究Encorafenib单药治疗的安全性和耐受性的多中心、开放性、I期研究
[Translation] A multicenter, open-label, phase I study to investigate the safety and tolerability of encorafenib monotherapy in Chinese patients with advanced metastatic solid tumors harboring BRAF V600E mutations
CTR20210687 / Active, not recruitingPhase 2
一项旨在评价Encorafenib和西妥昔单抗联合治疗对比伊立替康/西妥昔单抗或输注用5-氟尿嘧啶（5-FU）/亚叶酸（FA）/伊立替康（FOLFIRI）/西妥昔单抗在BRAF V600E突变的转移性结直肠癌中国患者中的疗效的多中心、随机的、开放性、双臂、II期研究（含安全性导入期）
[Translation] A multicenter, randomized, open-label, two-arm, phase II study to evaluate the efficacy of encorafenib plus cetuximab versus irinotecan/cetuximab or infusional 5-fluorouracil (5-FU)/leucovorin (FA)/irinotecan (FOLFIRI)/cetuximab in Chinese patients with metastatic colorectal cancer and BRAF V600E mutation (including a safety run-in phase)
CTR20170634 / CompletedPhase 3
一项多中心、随机、双盲、分层、安慰剂平行对照的评价帕洛诺司琼静脉给药的有效性和安全性研究
[Translation] A multicenter, randomized, double-blind, stratified, placebo-controlled parallel study to evaluate the efficacy and safety of intravenous palonosetron
100 Clinical Results associated with Pierre Fabre Médicament Production SAS
Login to view more data
0 Patents (Medical) associated with Pierre Fabre Médicament Production SAS
Login to view more data
100 Deals associated with Pierre Fabre Médicament Production SAS
Login to view more data
100 Translational Medicine associated with Pierre Fabre Médicament Production SAS
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
2
1
Phase 3 Clinical
Other
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free